Literature DB >> 18248617

Pre-synaptic dopaminergic compensation after moderate nigrostriatal damage in non-human primates.

Xiomara A Perez1, Neeraja Parameswaran, Luping Z Huang, Kathryn T O'Leary, Maryka Quik.   

Abstract

Despite a dramatic loss of nigrostriatal dopaminergic neurons in Parkinson's disease, clinical symptoms only arise with 70-80% reduction of striatal dopamine. The mechanisms responsible for this functional compensation are currently under debate. Although initial studies showed an enhanced pre-synaptic dopaminergic function with nigrostriatal degeneration, more recent work suggests that functional compensation is not dopamine-mediated. To address this issue, we used cyclic voltammetry to directly measure endogenous dopamine release from striatal slices of control monkeys and animals with a moderate or severe MPTP-induced dopaminergic lesion. The moderately lesioned monkeys were asymptomatic, while the severely lesioned animals were parkinsonian. In monkeys with a moderate lesion, a 300% increase was obtained in endogenous striatal dopamine release. In contrast, in striatal slices from severely lesioned animals, a small % of evoked dopamine signals were similar in amplitude to control while the greater majority were undetectable. These findings suggest that pre-synaptic dopaminergic compensation develops in residual dopaminergic terminals with moderate lesioning, but that this response is lost with severe nigrostriatal damage. Such an interpretation is supported by the results of dopamine turnover studies. This enhanced pre-synaptic dopaminergic activity may be important in maintaining normal motor function during the initial stages of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248617      PMCID: PMC3264543          DOI: 10.1111/j.1471-4159.2008.05268.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  54 in total

1.  "Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat.

Authors:  Brian P Bergstrom; Paul A Garris
Journal:  J Neurochem       Date:  2003-12       Impact factor: 5.372

2.  Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release.

Authors:  Lifen Zhang; Fu-Ming Zhou; John A Dani
Journal:  Mol Pharmacol       Date:  2004-09       Impact factor: 4.436

3.  How does Parkinson's disease begin? The role of compensatory mechanisms.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Jose L Lanciego; Manuel Rodriguez Diaz
Journal:  Trends Neurosci       Date:  2004-03       Impact factor: 13.837

4.  Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.

Authors:  Maryka Quik; Heather Cox; Neeraja Parameswaran; Kathryn O'Leary; J William Langston; Donato Di Monte
Journal:  Ann Neurol       Date:  2007-12       Impact factor: 10.422

Review 5.  Cholinergic interneuron characteristics and nicotinic properties in the striatum.

Authors:  Fu-Ming Zhou; Charles J Wilson; John A Dani
Journal:  J Neurobiol       Date:  2002-12

6.  Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.

Authors:  Ranjita Betarbet; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2004-10       Impact factor: 5.330

Review 7.  Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder.

Authors:  Thomas Wichmann; Mahlon R DeLong
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

Review 8.  Brain monoamines and parkinsonism.

Authors:  O Hornykiewicz
Journal:  Natl Inst Drug Abuse Res Monogr Ser       Date:  1975-11

9.  Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism.

Authors:  M J Zigmond; A L Acheson; M K Stachowiak; E M Stricker
Journal:  Arch Neurol       Date:  1984-08

Review 10.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

View more
  28 in total

1.  α6ß2* and α4ß2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: relevance to Parkinson's disease.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2010-08-23       Impact factor: 4.436

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens.

Authors:  Xiomara A Perez; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-10-13       Impact factor: 5.372

4.  Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.

Authors:  Joanna A Korecka; Elizabeth B Moloney; Ruben Eggers; Barbara Hobo; Sanny Scheffer; Nienke Ras-Verloop; R Jeroen Pasterkamp; Dick F Swaab; August B Smit; Ronald E van Kesteren; Koen Bossers; Joost Verhaagen
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

5.  Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum.

Authors:  Christopher D Howard; Kristen A Keefe; Paul A Garris; David P Daberkow
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

6.  Chronic Nicotine Mitigates Aberrant Inhibitory Motor Learning Induced by Motor Experience under Dopamine Deficiency.

Authors:  Jessica L Koranda; Anne C Krok; Jian Xu; Anis Contractor; Daniel S McGehee; Jeff A Beeler; Xiaoxi Zhuang
Journal:  J Neurosci       Date:  2016-05-11       Impact factor: 6.167

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

8.  Prominent role of alpha3/alpha6beta2* nAChRs in regulating evoked dopamine release in primate putamen: effect of long-term nicotine treatment.

Authors:  Xiomara A Perez; Kathryn T O'Leary; Neeraja Parameswaran; J Michael McIntosh; Maryka Quik
Journal:  Mol Pharmacol       Date:  2009-01-14       Impact factor: 4.436

9.  Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function.

Authors:  Xiomara A Perez; Tanuja Bordia; J Michael McIntosh; Sharon R Grady; Maryka Quik
Journal:  Mol Pharmacol       Date:  2008-06-26       Impact factor: 4.436

10.  Response monitoring in de novo patients with Parkinson's disease.

Authors:  Rita Willemssen; Thomas Müller; Michael Schwarz; Michael Falkenstein; Christian Beste
Journal:  PLoS One       Date:  2009-03-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.